He was labelled as an undifferentiated autoimmune disorder by the medical team and given a trial of prednisolone 30mg to which his CRP fell from 265 to 41. He was discharged with general medical follow-up and a prednisolone weaning regime. After 1 month he re-presented to the medical take with acute bilateral visual loss (on 15mg prednisolone). This was preceded by a 2-week history of bitemporal headaches. There was no history of polymyalgia, jaw claudication or scalp tenderness. Ocular examination revealed bilateral swollen optic discs. He was admitted and treated with pulsed intravenous methylprednisolone. An MRA of his head and neck showed intracranial irregularities consistent with a cerebral vasculitis. He was started on methotrexate alongside prednisolone and referred to the regional GCA centre for tocilizumab therapy. Discussion: The frequency of ophthalmic complications in GCA is quoted tobe as highas 30%. The case abovepresentedwithnon-specific symptoms and extremely raised inflammatory markers. Despite numerous investigations including a PET scan, a definitive diagnosis was not made without the final presentationof permanent bilateral visual loss. The patient had appropriate and timely investigations for his symptoms at initial admission (blood tests, cultures, CT and PET imaging). Positive findings were appropriately investigated further. Ultimately, he was trialled with prednisolone when infection and malignancy were excluded by the medical team and discharged with follow up. Unfortunately, he was then readmitted with a dramatic relapse.
The British Society for Rheumatology recommends starting methotrexate following recurrent relapses in GCA, but we decided to start methotrexate due to the aggressive nature of his disease (sudden onset visual loss and cerebral vasculitis on MRA). Few randomised controlled studies, case-control studies and metaanalyses have looked at the efficacy and steroid-sparing effects of methotrexate introduction at diagnosis of GCA to conflicting results. Jover et al. (2001) showed that low dose methotrexate (10mg) was effective in controlling GCA disease activity. This was supported by a metaanalysis (Mahr et al., 2007) and most recently in a retrospective case-control study (Koster et al., 2019) . The larger and well-designed Hoffman et al. (2002) trial showed a small benefit from methotrexate introduction but no statisticalsignificance. There hasbeen nolarge-trialconvincing evidence of methotrexate efficacy in GCA at introduction or for relapses and this is reflected in the national guidance. However, the trials above used relatively low doses of methotrexate. Some of the trial also had short follow-up times and with slow steroid weans possibly masking a positive methotrexate effect. Key learning points: Despite the vague and nondescript presentation of this patient, focusing on subtleties from the history and having a high index of suspicion arevital to making adiagnosis of GCA. The patient had a negative PET scan despite progression to severe disease within 1 month. PET studies have shown high sensitivity and specificity values for the diagnosis of large vessel inflammation in GCA (90% and 98% respectively -Soussan et al., 2015) . However, the lack of large vesselinvolvement onthis scan was falsely reassuring. Conflicts of interest: The authors have declared no conflicts of interest.
NOT EVERY RHEUMATOLOGIC HEADACHE IS GIANT CELL ARTERITIS: A CASE OF ASEPTIC MENINGITIS ON A BACKGROUND OF RHEUMATOID ARTHRITIS
Priyan Magan 1 , Muhamad Jasim 1 , and Nick Barkham 1 The Rheumatology Centre, New Cross Hospital, Wolverhampton, United Kingdom Introduction: A 65-year-old Caucasian lady had a background of longstanding seropositive rheumatoid arthritis (RA) for which multiple disease modifying drugs and biologics had been tried, but then stopped due to either inefficacy or intolerance. She presented with possible vasculitis and was initiallytreated and investigated for giant cell arteritis (GCA). Case description: This patient presented with temporal headache and right-sided visual field loss, with tenderness over a weakly palpable right temporal artery. No jaw claudication or other cranial nerve abnormality and peripheral nervous system examination was normal. She was commenced on prednisolone and the ophthalmologist decided against temporal artery biopsy. She subsequently developed episodes of tonicclonic seizure and reduced consciousness, which would be unexplained by GCA. ESR 70 and CRP 28. ANCA and ANA negative, rheumatoid factor positive and anti-CCP antibodies>600. Gadolinium-enhanced MRI brain showed subdural effusions in the left frontal/parietal lobes alongside effacement of the gyri, indicating lepatomeningitis. Lumbar puncture showed increased cerebral spinal fluid (CSF) protein of 1.25g/L (0.1-0.4) and mildly reduced glucose of 2.1mmol/ L (2.2-3.9). CSF was negative for acid fast bacilli, lyme disease, cryptococcal antigen, PCR for viruses and TB, culture and extensive immunological screening. Tuberculosis T-Spot test was negative whilst PET-CT demonstrated widespread polyarthropathy but no evidence of an underlying malignancy. The patient was referred for meningeal biopsy; however it was considered too high-risk given her medical co-morbidities. As an inpatient, she developed pneumonia and two myocardial infarctions. For the next four months, she was seizure-free on levetiracetam, but still experienced right-sided facial twitching. She was commenced on a reducing regime of prednisolone on the assumption of rheumatoid meningitis and also given 12-month empirical therapy to cover for possibility of TB meningitis, although this was deemed less likely. Initially she responded to prednisolone but upon dose reduction, she noticed worsening incoordination and unsteadiness, with simultaneous joint flare-up, indicating that immunosuppression was beneficial to her neurological status. Azathioprine was introduced as a steroid-sparing agent but she developed abnormal liver function and hence mycophenolate has been used instead. No side effects have been reported; she has remained seizure-free and reports an improvement in her neurological status. Discussion: Initially it was appropriate to treat as GCA given very typical history. However, the presence of other unexplained symptoms and MRI findings led the decision that the diagnosis was not purely vasculitic in origin. MRI brain and CSF findings were consistent with aseptic meningitis, typically where there is meningeal inflammation with negative Gram stain and culture of CSF, often with pleocytosis. Although predominantly caused by enteroviruses; it can occur secondary to malignancy, drugs and autoimmune disease. These causes were considered, however the presence of active rheumatoid arthritis made a diagnosis of rheumatoid meningitis likely. This uncommon complication of seropositive rheumatoid arthritis was described by Bathon et al as having three hallmark neuropathological findings; rheumatoid nodules, pachymeningitis and vasculitis. A diagnostic challenge is the lack of correlation between synovitis and neurological presentation. Presentation ranges from cranial/ peripheral nerve dysfunction to seizures and altered mental state. In the CSF we expect to find high protein and reduced glucose with sporadic pleocytosis. Findings from MRI and CSF analysis can be variable. Ultimately rheumatoid meningitis as described in the literature is diagnosed by histopathology at biopsy, but this is not always available in clinical practice, and sometimes empirical treatment has tobe given. Key learning points: Rheumatoid meningitis is a rare complication of RA, but can present with stroke-like episodes or seizures, so this diagnosis should always be considered in RA patients presenting in such a way. Despite high mortality and the lack of any evidence-based guidelines, combinations of steroids alongside cyclophosphamide, azathioprine and methotrexate are reported to have improved prognosis in some patients. The lack of any RCT evidence means the condition has to be managed according to expert opinion, which may require close co-operation between specialties such as neurology, infectious diseases and rheumatology to achieve a good outcome. Conflicts of interest: The authors have declared no conflicts of interest.
AN UNCOMMON CAUSE OF PYREXIA OF UNKNOWN ORIGIN
Noora Soobraty 1 , and Michael Green 2 1 Department of Rheumatology, Midyorks NHS Trust, Wakefield, United Kingdom, and 2 Rheumatology, York Teaching Hospital NHS Foundation Trust, York, United Kingdom Introduction: We report the case of a 58-year-old lady with pre-existing primary pulmonary hypertension presenting with a pyrexia of unknown origin (PUO). On review of her previous CT imaging, it was noted that the aortic wall was thickened which prompted further investigations in the form of a PET CT and IgG subclasses that led to the final diagnosis of large vessel vasculitis (LVV) and IgG4-related disease. She was successfully treated with prednisolone and mycofenolate mofetil (MMF). Interestingly she subsequently developed neurological symptoms and diagnosed with Miller-Fisher syndrome and further down the line she was diagnosed with adrenal insufficiency(AI). Case description: A 58-year-old lady was admitted under the cardiology team in April 2014 for investigation of a PUO. The patient also complained of worsening breathless on exertion, malaise and myalgia. Past medical history revealed pulmonary arterial hypertension (diagnosed 2000) with secondary right sided heart failure, an incidental secundum ASD defect and recurrent anterior uveitis. She was on sildenafil and warfarin long term. Clinical examination did not reveal any abnormal findings. Initial investigations to rule out a bacterial cause for her symptoms were 
